12750 HIGH BLUFF DRIVE SUITE 475, SAN DIEGO, CA
Belite Bio Submits New Drug Application in Japan for Tinlarebant
Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease
Announces Availability of Annual Report on Form 20-F Through Company Website
Material disclosure
Annual and Transition Report of Foreign Private Issuers
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
No filings found
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Prospectus filed pursuant to Rule 424(b)(7)
Correspondence
Submission Upload